Biomarkers in Lupus Nephritis

Anup Manoharan, Michael P. Madaio

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Biomarkers have the potential to be useful tools for noninvasively evaluating and managing patients with lupus nephritis. Many candidate biomarkers have been identified, but they require validation in larger cohorts. It is likely that combinations or biomarker profiles, rather than individual markers, will emerge to help better predict the severity of inflammation, the extent of fibrosis, degree of drug responsiveness, and other variables. This approach has the potential to reduce the use of the renal biopsy, improve therapeutic efficacy, and limit toxicity. We predict algorithms based on genotype and biomarkers combined with clinical presentation will emerge to help guide physicians in management. Assays that show the most potential include serum erythrocyte bound complement C4d, interleukin 17, interleukin 23, interferon score/chemokine score ratio, and anti-C1q antibodies. Such urinary biomarkers as fractional excretion of endothelial-1, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1, and TWEAK (tumor necrosis factor-like weak inducer of apoptosis) may also be useful but require validations.

Original languageEnglish (US)
Pages (from-to)131-143
Number of pages13
JournalRheumatic Disease Clinics of North America
Volume36
Issue number1
DOIs
StatePublished - Feb 1 2010

Fingerprint

Lupus Nephritis
Biomarkers
Interleukin-23
Interleukin-17
Vascular Cell Adhesion Molecule-1
Chemokine CCL2
Chemokines
Interferons
Anti-Idiotypic Antibodies
Fibrosis
Tumor Necrosis Factor-alpha
Erythrocytes
Genotype
Apoptosis
Inflammation
Physicians
Kidney
Biopsy
Serum
Pharmaceutical Preparations

Keywords

  • Assessment of renal functional activity
  • Indicators of Renal flare
  • Noninvasive biomarkers
  • Serologic markers
  • Urinary markers

ASJC Scopus subject areas

  • Rheumatology

Cite this

Biomarkers in Lupus Nephritis. / Manoharan, Anup; Madaio, Michael P.

In: Rheumatic Disease Clinics of North America, Vol. 36, No. 1, 01.02.2010, p. 131-143.

Research output: Contribution to journalReview article

Manoharan, Anup ; Madaio, Michael P. / Biomarkers in Lupus Nephritis. In: Rheumatic Disease Clinics of North America. 2010 ; Vol. 36, No. 1. pp. 131-143.
@article{c640f1171ebf4b1baef15b64f300ef09,
title = "Biomarkers in Lupus Nephritis",
abstract = "Biomarkers have the potential to be useful tools for noninvasively evaluating and managing patients with lupus nephritis. Many candidate biomarkers have been identified, but they require validation in larger cohorts. It is likely that combinations or biomarker profiles, rather than individual markers, will emerge to help better predict the severity of inflammation, the extent of fibrosis, degree of drug responsiveness, and other variables. This approach has the potential to reduce the use of the renal biopsy, improve therapeutic efficacy, and limit toxicity. We predict algorithms based on genotype and biomarkers combined with clinical presentation will emerge to help guide physicians in management. Assays that show the most potential include serum erythrocyte bound complement C4d, interleukin 17, interleukin 23, interferon score/chemokine score ratio, and anti-C1q antibodies. Such urinary biomarkers as fractional excretion of endothelial-1, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1, and TWEAK (tumor necrosis factor-like weak inducer of apoptosis) may also be useful but require validations.",
keywords = "Assessment of renal functional activity, Indicators of Renal flare, Noninvasive biomarkers, Serologic markers, Urinary markers",
author = "Anup Manoharan and Madaio, {Michael P.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1016/j.rdc.2009.12.009",
language = "English (US)",
volume = "36",
pages = "131--143",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Biomarkers in Lupus Nephritis

AU - Manoharan, Anup

AU - Madaio, Michael P.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Biomarkers have the potential to be useful tools for noninvasively evaluating and managing patients with lupus nephritis. Many candidate biomarkers have been identified, but they require validation in larger cohorts. It is likely that combinations or biomarker profiles, rather than individual markers, will emerge to help better predict the severity of inflammation, the extent of fibrosis, degree of drug responsiveness, and other variables. This approach has the potential to reduce the use of the renal biopsy, improve therapeutic efficacy, and limit toxicity. We predict algorithms based on genotype and biomarkers combined with clinical presentation will emerge to help guide physicians in management. Assays that show the most potential include serum erythrocyte bound complement C4d, interleukin 17, interleukin 23, interferon score/chemokine score ratio, and anti-C1q antibodies. Such urinary biomarkers as fractional excretion of endothelial-1, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1, and TWEAK (tumor necrosis factor-like weak inducer of apoptosis) may also be useful but require validations.

AB - Biomarkers have the potential to be useful tools for noninvasively evaluating and managing patients with lupus nephritis. Many candidate biomarkers have been identified, but they require validation in larger cohorts. It is likely that combinations or biomarker profiles, rather than individual markers, will emerge to help better predict the severity of inflammation, the extent of fibrosis, degree of drug responsiveness, and other variables. This approach has the potential to reduce the use of the renal biopsy, improve therapeutic efficacy, and limit toxicity. We predict algorithms based on genotype and biomarkers combined with clinical presentation will emerge to help guide physicians in management. Assays that show the most potential include serum erythrocyte bound complement C4d, interleukin 17, interleukin 23, interferon score/chemokine score ratio, and anti-C1q antibodies. Such urinary biomarkers as fractional excretion of endothelial-1, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1, and TWEAK (tumor necrosis factor-like weak inducer of apoptosis) may also be useful but require validations.

KW - Assessment of renal functional activity

KW - Indicators of Renal flare

KW - Noninvasive biomarkers

KW - Serologic markers

KW - Urinary markers

UR - http://www.scopus.com/inward/record.url?scp=77349100640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77349100640&partnerID=8YFLogxK

U2 - 10.1016/j.rdc.2009.12.009

DO - 10.1016/j.rdc.2009.12.009

M3 - Review article

C2 - 20202595

AN - SCOPUS:77349100640

VL - 36

SP - 131

EP - 143

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 1

ER -